CymaBay Therapeutics, Inc.(CBAY) Stock Research - Grey Stern Research

CymaBay Therapeutics, Inc. (CBAY) Stock Analysis

$32.48 (0.03%)

CBAY Financial Performance


Use the table below to view CymaBay Therapeutics, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2023

Metric Value Ranking among Peers
Price $32.48 -
52 Week Low $7.26 -
52 Week High $32.50 -
Market Cap $3.7 Billion 4/18
Gross Margin 2% 9/18
Profit Margin -100% 13/18
EBITDA margin -74460% 18/18
Q4 - 2023 Revenue $57,000 9/18
Q4 - 2023 Earnings -$41.9 Million 11/18
Q4 - 2023 Free Cash Flow -$27.6 Million 8/18
Trailing 4 Quarters Revenue $31.1 Million 7/18
Trailing 4 Quarters Earnings -$111.7 Million 12/18
Quarterly Earnings Growth -15% 9/18
Annual Earnings Growth 6% 6/18
Quarterly Revenue Growth 0% 5/18
Annual Revenue Growth 0% 5/18
Cash On Hand $206.5 Million 3/18
Short Term Debt $10.0 Million 2/18
Long Term Debt $99.2 Million 4/18

CymaBay Therapeutics, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare CymaBay Therapeutics, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 2/18
PS 119.98 2/18
PB 12.76 1/18
PC 18.05 5/18
Liabilities to Equity 0.49 6/18
ROA -0.26 8/18
ROE -0.38 9/18
Current Ratio 3.05 12/18
Quick Ratio 2.77 10/18
Long Term Debt to Equity 0.34 4/18
Debt to Equity 0.39 4/18
Burn Rate 4.27 4/18
Cash to Cap 0.06 14/18
CCR 0.66 14/18
EV to EBITDA -85.67 15/18
EV to Revenue 117.02 2/18

Company Details

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

CEO: Mr. Sujal Shah

Website: https://www.cymabay.com

Address: 7575 Gateway Blvd Ste 110 Newark California, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Biotechnology

CymaBay Therapeutics, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to CymaBay Therapeutics, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Viking Therapeutics, Inc. VKTX $3.2 Billion
Madrigal Pharmaceuticals, Inc. MDGL $7.5 Billion
Gossamer Bio, Inc. GOSS $315.8 Million
Homology Medicines, Inc. FIXX $3.0 Million
Karuna Therapeutics, Inc. KRTX $12.6 Billion
Kiniksa Pharmaceuticals, Ltd. KNSA $1.7 Billion
Stoke Therapeutics, Inc. STOK $440.7 Million
X4 Pharmaceuticals, Inc. XFOR $53.4 Million
Phathom Pharmaceuticals, Inc. PHAT $433.8 Million
89bio, Inc. ETNB $1.2 Billion
Pliant Therapeutics, Inc. PLRX $94.9 Million
Inozyme Pharma, Inc. INZY $62.6 Million
Biomea Fusion, Inc. BMEA $104.0 Million
Terns Pharmaceuticals, Inc. TERN $284.5 Million
Day One Biopharmaceuticals, Inc. DAWN $834.2 Million
Acumen Pharmaceuticals, Inc. ABOS $72.1 Million
Arcellx, Inc. ACLX $3.8 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
CBAY Income Statements
Quarter Year Revenue Earnings
Q4 2023 $ 57,000 -$41.9 Million
Q3 2023 $ 0 -$33.9 Million
Q2 2023 $ 31.0 Million -$808,000
Q1 2023 $ 0 -$35.1 Million
Q4 2022 $ 0 -$36.4 Million
Q3 2022 $ 0 -$27.6 Million
Q2 2022 $ 0 -$27.1 Million
Q1 2022 $ 0 -$27.8 Million

View All

CBAY Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2023 $206.5 Million $434.7 Million $114.5 Million $292.3 Million
Q3 2023 $273.7 Million $451.0 Million $104.3 Million $326.2 Million
Q2 2023 $35.5 Million $226.7 Million $99.6 Million $108.4 Million
Q1 2023 $59.2 Million $245.3 Million $95.2 Million $104.2 Million
Q4 2022 $20.3 Million $141.9 Million $90.9 Million $36.2 Million
Q3 2022 $30.7 Million $159.2 Million $87.0 Million $60.2 Million
Q2 2022 $52.8 Million $177.7 Million $374,000 $82.5 Million
Q1 2022 $74.0 Million $200.6 Million $537,000 $107.4 Million

View All

CBAY Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2023 -$27.6 Million -$180,000 -$67.2 Million
Q3 2023 -$26.1 Million $0 $238.2 Million
Q2 2023 -$25.5 Million -$70,000 -$23.7 Million
Q1 2023 $6.2 Million -$195,000 $38.9 Million
Q4 2022 -$18.8 Million -$13,000 -$10.4 Million
Q3 2022 -$17.5 Million -$11,000 -$22.1 Million
Q2 2022 -$22.6 Million -$124,000 -$21.2 Million
Q1 2022 -$25.4 Million $0 -$51.8 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions